摘要
背景：糖原合酶激酶（GSK）-3β和脑源性神经营养因子（BDNF）在轻度认知障碍（MCI）和2型糖尿病（T2DM）中起着至关重要的作用。潜在的机制可能涉及炎症和氧化应激。 目的：探讨老年T2DM患者中GSK-3β/ BDNF比值与MCI的相关性，以及GSK-3β/ BDNF比值是否可作为M2并发T2DM（MD）的新诊断生物标志物。 方法：根据认知水平和GSK-3β/ BDNF比值四分位数对326例中国老年T2DM患者进行分类。根据国家老年痴呆协会协会工作组标准诊断出MCI。除常规血尿和生化检查外，还使用蒙特利尔认知评估量表（MoCA）评估认知功能，并使用ELISA方法测量GSK-3β活性和血清BDNF，白介素1β（IL-1β）的水平，高迁移率族box-1（HMGB1）蛋白，丙二醛（MDA）和8-isoprostaglandinF2α（8-iso-PGF2α）。 结果：我们发现GSK-3β活性与BDNF呈负相关（r = -0.270，P = 0.008），而GSK-3β/ BDNF比值较高的患者的MoCA评分较低（P = 0.001）。与没有MCI（nMD）的T2DM患者相比，MD患者的GSK-3β活性和GSK-3β/ BDNF比率更高，但BDNF水平较低。至于炎症和氧化应激，IL-1β与GSK-3β活性呈负相关，而8-isoPGF2α与GSK-3β活性和GSK-3β/ BDNF比值呈正相关。当GSK-3β/ BDNF比值四分位数从最低值升高到最高值时，MCI的优势比逐渐增加（6.90，95％CI 3.22-14.78）。相反，MoCA评分与GSK-3β/ BDNF比，年龄和快速血糖（FBG）相关，其中GSK-3β/ BDNF比对认知的影响最大（β= -0.199，P <0.001）。 结论：我们的数据提供了GSK-3β/ BDNF比值与MCI之间密切联系的证据。与单独使用GSK-3β或BDNF相比，GSK-3β/ BDNF比率可以作为更好的MD诊断生物标志物，并且增加的GSK-3β/ BDNF比率表明认知功能较差。
关键词: 轻度认知障碍，2型糖尿病，糖原合成酶激酶-3β，脑源性神经营养因子，炎症，氧化应激。
[1]
Pu D, Zhao Y, Chen J, Sun Y, Lv A, Zhu S, et al. Protective effects of sulforaphane on cognitive impairments and AD-like lesions in diabetic mice are associated with the upregulation of Nrf2 transcription activity. Neuroscience 381: 35-45. (2018).
[2]
Zhai Y, Meng X, Ye T, Xie W, Sun G, Sun X, et al. Inhibiting the NLRP3 inflammasome activation with MCC950 ameliorates diabetic encephalopathy in db/db mice. Molecules 23(3): 522. (2018).
[3]
Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis 12(1): 23-35. (2007).
[4]
Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer’s disease. Biol Psychiatry 71(9): 805-13. (2012).
[5]
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3): 183-94. (2004).
[6]
Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. JAMA Neurol 61(5): 661-6. (2004).
[7]
Cheng PY, Sy HN, Wu SL, Wang WF, Chen YY. Newly diagnosed type 2 diabetes and risk of dementia: a population-based 7-year follow-up study in Taiwan. J Diabetes Complications 26(5): 382-7. (2012).
[8]
Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes & Endocrinol 2(3): 246-55. (2014).
[9]
Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, et al. Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67: 387-95. (2014).
[10]
Wang H, Kumar A, Lamont RJ. Scott DA3. GSK3beta and the control of infectious bacterial diseases. Trends Microbiol 22(4): 208-17. (2014).
[11]
Borror A. Brain-derived neurotrophic factor mediates cognitive improvements following acute exercise. Med Hypotheses 106: 1-5. (2017).
[12]
Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1-2): 27-39. (2001).
[13]
Bhat RV, Budd SL. GSK3beta signalling: casting a wide net in Alzheimer’s disease. Neurosignals 11(5): 251-61. (2002).
[14]
Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer’s disease. Neurosci Lett 373(1): 1-4. (2005).
[15]
Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HP, Diniz BS, et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res 45(2): 220-4. (2011).
[16]
Hemminqs BA, Yellowlees D, Cohen P. Glycogen synthase KINASE-3 from rabbit skeletal muscle. Methods Enzymol 99: 337-45. (1983).
[17]
Ko CY, Wang WL, Wang SM, Chu YY, Chang WC, Wang JM. Glycogen synthase kinase-3beta-mediated CCAAT/enhancer-binding protein delta phosphorylation in astrocytes promotes migration and activation of microglia/macrophages. Neurobiol Aging 35(1): 24-34. (2014).
[18]
Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3(6): 479-87. (2004).
[19]
Xu ZP, Yang SL, Zhao S, Zheng CH, Li HH, et al. Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: a multicentre, retrospective, nested case-control study. EBioMedicine 5: 105-13. (2016).
[20]
Datusalia AK, Sharma SS. Amelioration of diabetes-induced cognitive deficits by GSK-3beta inhibition is attributed to modulation of neurotransmitters and neuroinflammation. Mol Neurobiol 50(2): 390-405. (2014).
[21]
Wang X, Zhao L. Calycosin ameliorates diabetes-induced cognitive impairments in rats by reducing oxidative stress via the PI3K/Akt/GSK-3beta signaling pathway. Biochem Biophys Res Commun 473(2): 428-34. (2016).
[22]
Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15(3): 331-7. (2009).
[23]
Qin XY, Cao C, Cawley NX, Liu TT, Yuan J, Loh YP, et al. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N=7277). Mol Psychiatry 22(2): 312-20. (2017).
[24]
Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50(2): 431-8. (2007).
[25]
Boyuk B, Degirmencioglu S, Atalay H, Guzel S, Acar A, Celebi A, et al. Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus. J Diabetes Res 2014978143 (2014).
[26]
Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M. Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus. Exp Diabetes Res 20172823671 (2017).
[27]
Yang W, Dou KF, Song WJ. Prevalence of diabetes among men and women in China. N Engl J Med 362(12): 1090-101. (2010).
[28]
O’Driscoll C, Shaikh M. Cross-cultural applicability of the montreal cognitive assessment (MoCA): a systematic review. J Alzheimers Dis 58(3): 789-801. (2017).
[30]
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17(1): 37-49. (1982).
[31]
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3): 270-9. (2011).
[32]
Alberti KGMM, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med 15(7): 539-53. (1998).
[33]
Hayes AF, Scharkow M. The relative trustworthiness of inferential tests of the indirect effect in statistical mediation analysis: does method really matter? Psychol Sci 24(10): 1918-27. (2013).
[34]
Romero-Moreno R, Losada A, Márquez-González M, Mausbach BT. Stressors and anxiety in dementia caregiving: multiple mediation analysis of rumination, experiential avoidance, and leisure. Int Psychogeriatr 28(11): 1835-44. (2016).
[35]
Xu ZP, Gan GS, Liu YM, Xiao JS, Liu HX, Mei B, et al. Adiponectin attenuates streptozotocin-induced tau hyperphosphorylation and cognitive deficits by rescuing PI3K/Akt/GSK-3beta Pathway. Neurochem Res 43(2): 316-23. (2018).
[36]
Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan Y, et al. A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Front Aging Neurosci 6: 69. (2014).
[37]
Zheng T, Liu H, Qin L, Chen B, Zhang X, Hu X, et al. Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metabolism 87: 105-12. (2018).
[38]
Gao C, Hölscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 23(1): 1-11. (2011).
[39]
Price JB, Bronars C, Erhardt S, Cullen KR, Schwieler L, Berk M, et al. Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. Neurosci Biobehav Rev 90: 212-20. (2018).
[40]
Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer’s disease, mild cognitive impairment or Parkinson’s disease. J Neuroimmunol 283: 50-7. (2015).
[41]
Tian S, Huang R, Han J, Cai R, Guo D, Lin H, et al. Increased plasma Interleukin-1beta level is associated with memory deficits in type 2 diabetic patients with mild cognitive impairment. Psychoneuroendocrinology 96: 148-54. (2018).
Call for Papers in Thematic Issues
30 September, 2024
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
26
1